Cascara sagrada 450 mg
RxNorm 330301
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 330301 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: cascara sagrada 450 mg.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SCDC
Semantic Clinical Drug Component (SCDC):
Cascara sagrada 450 mg
(Atom ID: 12278541)
Patient Education
Cascara Sagrada
What is it? Cascara sagrada is a shrub. The dried bark is used to make medicine.
Cascara sagrada used to be approved by the U.S. Food and Drug Administration (FDA) as an over-the-counter (OTC) drug for constipation. However, over the years, concerns were raised about cascara sagrada's safety and effectiveness. The FDA gave manufacturers the chance to submit safety and effectiveness information to answer these concerns. But the companies decided the cost of conducting safety and effectiveness studies would likely be more than the profit they could expect from sales of cascara sagrada. So they didn't comply with the request. As a result, the FDA notified manufacturers to remove or reformulate all OTC laxative products containing cascara sagrada from the U.S. market by November 5, 2002. Today, you can buy cascara sagrada as a "dietary supplement", but not as a drug. "Dietary supplements" don't have to meet the standards that the FDA applies to OTC or prescription drugs.
Cascara sagrada is commonly used by mouth as a laxative for constipation.
In foods and beverages, a bitterless extract of cascara sagrada is sometimes used as a flavoring agent.
In manufacturing, cascara sagrada is used in the processing of some sunscreens.
[Learn More]
* Please review the disclaimer below.
